Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Fried S, Shkury E, Itzhaki O, Sdayoor I, et al. Leuk Lymphoma 2023 Aug 11:1-8. doi: 10.1080/10428194.2023.2246611.

Read + Share

Amedeo Smart

Independent Medical Education

Fried S, Shkury E, Itzhaki O, Sdayoor I, et al. Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leuk Lymphoma 2023 Aug 11:1-8. doi: 10.1080/10428194.2023.2246611.
PMID: 37565578